Pharma Mar Sau Stock Fundamentals
| 0RC6 Stock | 75.72 2.97 4.08% |
Pharma Mar SAU fundamentals help investors to digest information that contributes to Pharma Mar's financial success or failures. It also enables traders to predict the movement of Pharma Stock. The fundamental analysis module provides a way to measure Pharma Mar's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharma Mar stock.
At this time, Pharma Mar's Depreciation And Amortization is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 19.9 M in 2024, whereas Gross Profit is likely to drop slightly above 114 M in 2024. Pharma | Select Account or Indicator |
Pharma Mar SAU Company Current Valuation Analysis
Pharma Mar's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Pharma Mar Current Valuation | 1.23 B |
Most of Pharma Mar's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharma Mar SAU is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Pharma Mar SAU has a Current Valuation of 1.23 B. This is 83.04% lower than that of the Commercial Services & Supplies sector and significantly higher than that of the Industrials industry. The current valuation for all United Kingdom stocks is 92.57% higher than that of the company.
Pharma Mar SAU Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pharma Mar's current stock value. Our valuation model uses many indicators to compare Pharma Mar value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharma Mar competition to find correlations between indicators driving Pharma Mar's intrinsic value. More Info.Pharma Mar SAU is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharma Mar's earnings, one of the primary drivers of an investment's value.Pharma Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharma Mar's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharma Mar could also be used in its relative valuation, which is a method of valuing Pharma Mar by comparing valuation metrics of similar companies.Pharma Mar is currently under evaluation in current valuation category among its peers.
Pharma Fundamentals
| Return On Equity | 0.0032 | ||||
| Return On Asset | -0.0065 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 1.23 B | ||||
| Shares Outstanding | 221.28 M | ||||
| Shares Owned By Insiders | 21.39 % | ||||
| Shares Owned By Institutions | 7.21 % | ||||
| Price To Sales | 98.12 X | ||||
| Revenue | 158.15 M | ||||
| Gross Profit | 182.7 M | ||||
| EBITDA | 4.55 M | ||||
| Net Income | 1.14 M | ||||
| Total Debt | 43.67 M | ||||
| Book Value Per Share | 10.39 X | ||||
| Cash Flow From Operations | (13.45 M) | ||||
| Earnings Per Share | 5.03 X | ||||
| Number Of Employees | 509 | ||||
| Beta | 0.044 | ||||
| Market Capitalization | 16.39 B | ||||
| Total Asset | 341.22 M | ||||
| Retained Earnings | 142.22 M | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 341.22 M | ||||
| Last Dividend Paid | 0.65 |
About Pharma Mar Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharma Mar SAU's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharma Mar using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharma Mar SAU based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 25.9 M | 19.8 M | |
| Total Revenue | 158.2 M | 146.3 M | |
| Cost Of Revenue | 9.6 M | 9.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pharma Stock Analysis
When running Pharma Mar's price analysis, check to measure Pharma Mar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Mar is operating at the current time. Most of Pharma Mar's value examination focuses on studying past and present price action to predict the probability of Pharma Mar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Mar's price. Additionally, you may evaluate how the addition of Pharma Mar to your portfolios can decrease your overall portfolio volatility.